Download PDF
Seminars in Neurosurgery 2001; 12(2): 245-252
DOI: 10.1055/s-2001-17130
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Neurotransplantation and Protective Therapy for Movement Disorders

Roy A. E. Bakay
  • Rush Presbyterian-St. Luke's Medical Center, Chicago Institute of Neurosurgery and Neuroresearch, Chicago, IL
Further Information

Publication History

Publication Date:
13 September 2001 (online)

    Permissions and Reprints

ABSTRACT

Over the past decade a number of advances in cell biology opened new frontiers for surgical treatment of movement disorders. Neurotransplantation as replacement therapy has recently undergone a proof of principle but it is still not fully accepted. The newest surgical approach is protective therapy where innovative techniques are still being developed. Although this has the greatest promise for the future, it also has the greatest number of technical hurdles to overcome before it can become standard therapy. The present status of these new surgical interventions for Parkinson's disease (PD) is reviewed and clinical results are discussed.

KEYWORD

Neurotransplantation - Parkinson's disease - movement disorders - protective therapy

REFERENCES

  • 1 Bakay R AE, Kordower J, Starr P. Restorative surgical therapies for Parkinson's disease.  CNS Regeneration . 1999;  14 389-417
    PubMedGoogle Scholar
  • 2 Boyer K L, Bakay R AE. The history, theory, and present status of brain transplantation.  Neurosurg Clin N Amer . 1995;  6(1) 113-125
    PubMedGoogle Scholar
  • 3 Defer G, Geny C, Ricolfi F. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach.  Brain . 1996;  119 41-50
    PubMedGoogle Scholar
  • 4 Folkerth R, Durso R. Survival and proliferation of nonneural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts.  Neurology . 1996;  46 1219-1224
    PubMedGoogle Scholar
  • 5 Freed, C, Breeze R, Rosenberg N. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease.  N Engl J Med . 1992;  327(22) 1549-1555
    PubMedGoogle Scholar
  • 6 Freed C, Greene P, Breeze R. Transplantation of embryonic dopamine neurons for severe Parkinson's disease.  N Engl J Med . 2001;  344 710-719
    CrossrefPubMedGoogle Scholar
  • 7 Freeman T, Olanow C, Hauser R. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease.  Ann Neurol . 1995;  38 379-388
    CrossrefPubMedGoogle Scholar
  • 8 Freeman T, Sanberg P, Nauert G, Boss B, Spector D, Olanow C. The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts.  Cell Transplant . 1995;  4 141-154
    PubMedGoogle Scholar
  • 9 Hauser R A, Freeman T B, Snow B J. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson's disease.  Arch Neurol . 1999;  56 179-187
    CrossrefPubMedGoogle Scholar
  • 10 Henderson B T, Clough C G, Hughes R C, Hitchcock E R, Kenny B G. Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease.  Arch Neurol . 1991;  48 822-827
    PubMedGoogle Scholar
  • 11 Hitchcock E. Current trends in neural transplantation.  Neurol Res . 1995;  17 33-37
    PubMedGoogle Scholar
  • 12 Hitchcock E, Whitwell H, Sofroniew M, Bankiewicz K. Survival of TH-positive and neuromelanin-containing cells in patients with Parkinson's disease after intrastriatal grafting of fetal ventral mesencephalon [abstract].  Exp Neurol . 1994;  129 3
    CrossrefPubMedGoogle Scholar
  • 13 Hoffer B, Leenders K, Young D. Eighteen-month course of two patients with grafts of fetal dopamine neurons for severe Parkinson's disease.  Exp Neurol . 1992;  188 243-252
    PubMedGoogle Scholar
  • 14 Huang S, Pei G, Kang F. Transplant operation of human fetal substantia nigra tissue to caudate nucleus in Parkinson's disease: first clinical trials.  Clin J Neurosurg . 1989;  5(3) 210-213
    PubMedGoogle Scholar
  • 15 Iacono R, Tang Z, Mazziotta J, Grafton S, Hoehn M. Bilateral fetal grafts for Parkinson's disease: 22 months' results.  Stereotact Funct Neurosurg . 1992;  58 84-87
    PubMedGoogle Scholar
  • 16 Jacques D B, Kopyov O V, Eagle K S, Carter T, Lieberman A. Outcomes and complications of fetal tissue transplantation in Parkinson's disease.  Stereotact Funct Neurosurg . 1999;  72 219-224
    PubMedGoogle Scholar
  • 17 Kopyov O, Jacques D, Lieberman A, Duma C, Rogers R. Clinical study of fetal mesencephalic intracerebral transplants for the treatment of Parkinson's disease.  Cell Transplant . 1996;  5 327-337
    PubMedGoogle Scholar
  • 18 Kordower J, Freeman T, Snow B. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease.  N Engl J Med . 1995;  332 1118-1124
    CrossrefPubMedGoogle Scholar
  • 19 Kordower J H, Freeman T B, Chen E Y. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease.  Mov Disord . 1998;  13 383-393
    CrossrefPubMedGoogle Scholar
  • 20 Lindvall O. Neural transplantation: a hope for patients with Parkinson's disease.  NeuroReport . 1997;  8(14) iii-x
    PubMedGoogle Scholar
  • 21 Lindvall O, Brundin P, Widner H. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease.  Science . 1990;  247 574-577
    PubMedGoogle Scholar
  • 22 Lindvall O, Sawle G, Widner H. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease.  Ann Neurol . 1994;  35 172-180
    CrossrefPubMedGoogle Scholar
  • 23 Lopez-Lozano J, Bravo B, Brera B. Long-term follow-up in 10 Parkinson's disease patients subjected to fetal brain grafting into a cavity in the caudate nucleus: the Clinica Puerta de Hierro experience.  Transplantation Proc . 1995;  27 1395-1400
    PubMedGoogle Scholar
  • 24 Lopez-Lozano J, Bravo G, Brera B. Long-term improvement in patients with severe Parkinson's disease after implantation of fetal ventral mesencephalic tissue in a cavity of the caudate nucleus: 5-year follow-up in 10 patients.  J Neurosurg . 1997;  86 931-942
    PubMedGoogle Scholar
  • 25 Madrazo I, Franco-Bourland R, Ostrosky-Solid F. Fetal homotransplants (ventral mesencephalon and adrenal tissue) to the striatum of Parkinson subjects.  Arch Neurol . 1990;  47 1281-1285
    PubMedGoogle Scholar
  • 26 Meyer C, Detta A, Kudoh C. Hitchcock's experimental series of focal implants for Parkinson's disease: cografting of ventral mesencephalon and striatum.  Acta Neurochir Suppl . 1995;  64 1-4
    PubMedGoogle Scholar
  • 27 Molina H, Quinones-Molina R, Munoz J. Neurotransplantation in Parkinson's disease: from open microsurgery to bilateral stereotactic approach: first clinical trial using microelectrode recording.  Stereotact Funct Neurosurg . 1994;  62 204-208
    PubMedGoogle Scholar
  • 28 Peschanski M, Defer G, N'Guyen J. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon.  Brain . 1994;  117 487-499
    PubMedGoogle Scholar
  • 29 Redmond D, Leranth C, Spencer D. Fetal neural graft survival [letter].  Lancet . 1990;  336 820-822
    PubMedGoogle Scholar
  • 30 Remy P, Samson Y, Hantraye P. Clinical correlates of [18-F] fluorodopa uptake in five grafted parkinsonian patients.  Ann Neurol . 1995;  38 580-588
    CrossrefPubMedGoogle Scholar
  • 31 Spencer D, Robbins R, Naftolin F. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of parkinsonian patients: functional effects for 18 months.  New Engl J Med . 1992;  327(22) 1541-1548
    PubMedGoogle Scholar
  • 32 Subrt O, Tichy M, Vladyka V, Hurt K. Grafting of fetal dopamine neurons in Parkinson's disease: the Czech experience with severe akinetic patients.  Acta Neurochir Suppl (Wien) . 1991;  52 51-53
    PubMedGoogle Scholar
  • 33 Wenning G, Odin P, Morrish P. Short-and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease.  Ann Neurol . 1997;  42 95-107
    CrossrefPubMedGoogle Scholar
  • 34 Widner H, Tetrud J, Rehncrona S. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).  N Engl J Med . 1992;  327 1556-1563
    PubMedGoogle Scholar
  • 35 Yurek D, Collier T, Sladek J. Embryonic mesencephalic and striatal co-grafts: development of grafted dopamine neurons and functional recovery.  Exp Neurol . 1990;  109 191-199
    CrossrefPubMedGoogle Scholar
  • 36 Zabek M, Mazurowski W, Dymecki J. A long-term follow-up of fetal dopaminergic neuronal transplantation into the brains of three parkinsonian patients.  Res Neurol Neurosci . 1994;  6 97-106
    PubMedGoogle Scholar
  • 37 Widner H, Brundin P. Immunological aspects of grafting in the mammalian central nervous system: a review and speculative synthesis.  Brain Res . 1998;  Rev 13 287-324
    PubMedGoogle Scholar
  • 38 Grabowska A, Lampson L. Expression of class I and II major histocompatibility (MHC) antigens in the developing of CNS.  J Neural Transplantation Plasticity . 1992;  3 204-205
    PubMedGoogle Scholar
  • 39 Lawrence J, Morris R, Wilson D. Mechanisms of allograft rejection in the rat brain.  Neuroscience . 1990;  37 431-462
    CrossrefPubMedGoogle Scholar
  • 40 Skoskiewicz M, Colvin R, Scheenberger E. Widespread and elective distribution of major histocompatibility complex-determined antigens in vivo by interferon.  J Exp Med . 1985;  152 1645-1664
    PubMedGoogle Scholar
  • 41 Poltorak M, Freed W. Immunological reactions induced by intracerebral transplantations: evidence that host microglia but not astroglia are the antigen-presenting cells.  Exp Neurol . 1989;  103 222-233
    CrossrefPubMedGoogle Scholar
  • 42 Vidovic M, Sparacia S, Elovitz M, Beneviste E. Induction and regulation of class II major histocompatability complex mRNA expression in astrocytes by interferon-gamma and tumor necrosis factor-alpha.  J Neuroimmunol . 1990;  30 89-200
    PubMedGoogle Scholar
  • 43 Hirshberg D, Schwartz M. Macrophage recruitment to acutely injured central nervous system is inhibited by a resident factor: a basis for an immune-brain barrier.  J Neuroimmunol . 1995;  61 89-96
    CrossrefPubMedGoogle Scholar
  • 44 Bakay R AE, Boyer K L, Freed C R, Ansari A A. Immunological responses to injury and grafting in the central nervous system of nonhuman primates.  Cell Transplant . 1998;  7(2) 109-120
    PubMedGoogle Scholar
  • 45 Fiandaca M, Bakay R AE, Sweeney K, Chan W. Immunologic response to intracerebral fetal neural allografts in the rhesus monkey.  Prog Brain Res . 1988;  78 287-296
    PubMedGoogle Scholar
  • 46 Freed C, Breeze R, Schneck S, Bakay R AE, Ansari A. Fetal neural transplantation for Parkinson's disease. In: Clinical Immunology: Principles and Practice New York, NY: Mosby 1996: 1677-1687
    Google Scholar
  • 47 Kordower J, Styren S, Clarke M, DeKosky S, Olanow C, Freeman T. Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants.  Cell Transplant . 1997;  6 213-219
    PubMedGoogle Scholar
  • 48 Piccini P, Brooks D J, Bjorklund A. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient.  Nat Neurosci . 1999;  2 1137-1140
    CrossrefPubMedGoogle Scholar
  • 49 Brundin P, Karlsson J, Emgard M. Improving the survival of grafted dopaminergic neurons: a review over current approaches.  Cell Transplant . 2000;  9 179-195
    PubMedGoogle Scholar
  • 50 Greene P E, Fahn S, Tsai W Y. Severe spontaneous dyskinesias: a disabling complication of embryonic dopaminergic tissue implants in a subset of transplanted patients with advanced Parkinson's disease [abstract].  Mov Disord . 1999;  14 904
    PubMedGoogle Scholar
  • 51 Mamelak A N, Eggerding F A, Oh D S. Fatal cyst formation after fetal mesencephalic allograft transplant for Parkinson's disease.  J Neurosurg . 1998;  89 592-598
    PubMedGoogle Scholar
  • 52 Mendez I, Dagher A, Hong M. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations.  J Neurosurg . 2000;  92 863-869
    PubMedGoogle Scholar
  • 53 Sladek J R, Collier T J, Elsworth J D, Taylor J R, Roth R H, Redmond D E. Can graft-derived neurotrophic activity be used to direct axonal outgrowth of grafted dopamine neurons for circuit reconstruction in primates?.  Exp Neurol . 1993;  124 134-139
    CrossrefPubMedGoogle Scholar
  • 54 Vawter D, Gervais K, Caplan A. Risks of fetal tissue donation to women.  J Neural Transplantation Plasticity . 1992;  3 322
    PubMedGoogle Scholar
  • 55 Svendsen C, Smith A. New prospects for human stem-cell therapy in the nervous system.  Trends Neurosci . 1999;  22 357-364
    CrossrefPubMedGoogle Scholar
  • 56 Deacon T, Schumacher J, Dinsmore J. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease.  Nature Med . 1995;  3 350-353
    PubMedGoogle Scholar
  • 57 Edge A, Dinsmore J. Xenotransplantation in the central nervous system.  Xeno . 1997;  5(2) 23-25
    PubMedGoogle Scholar
  • 58 Deacon T, Pakzaban P, Burns L, Dinsmore J, Isacson O. Cytoarchitectonic development, axon-glia relationships, and long distance axon growth of porcine striatal xenografts in rats.  Exp Neurol . 1994;  130 151-167
    CrossrefPubMedGoogle Scholar
  • 59 Isacson O, Deacon T, Pakzaban P, Galpern W, Dinsmore J, Burns L. Transplanted xenogenetic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres.  Nature Med . 1995;  1 1189-1194
    PubMedGoogle Scholar
  • 60 Wu C, De Zhou M, Bao X. The combined method of transplantation of fetal substantia nigra and stereotactic thalamotomy for Parkinson's disease.  Br J Neurosurg . 1994;  8 709-716
    PubMedGoogle Scholar
  • 61 Fisher L J, Jinnah H A, Kale L C, Higgins G A, Gage F H. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa.  Neuron . 1991;  6 371-380
    CrossrefPubMedGoogle Scholar
  • 62 Jiao S, Gurevich V, Wolff J. Long-term correction of a rat model of Parkinson's disease by gene therapy.  Nature . 1993;  362 450-453
    CrossrefPubMedGoogle Scholar
  • 63 Anton R. Neural-targeted gene therapy for rodent and primate hemiparkinsonism.  Exp Neurol . 1994;  127 199-206
    CrossrefPubMedGoogle Scholar
  • 64 Bredesen D. Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: immunological aspects, spontaneous and drug-induced behavior, and dopamine release.  Exp Brain Res . 1988;  70 192-208
    PubMedGoogle Scholar
  • 65 Bjorklund A, Lindvall O. Dopamine in dendrites of the substantia nigra neurons: suggestions for a role in dendritic terminals.  Brain Res . 1975;  83 531-537
    CrossrefPubMedGoogle Scholar
  • 66 Johnson R, Becker J. Intranigral grafts of fetal ventral mesencephalic tissue in adult 6-hydroxydopamine-lesioned rats can induce behavioral recovery.  Cell Transplant . 1997;  6 267-276
    PubMedGoogle Scholar
  • 67 Nikkah G, Bentlage C, Cunningham M G, Bjorklund A. Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson mode.  J Neurosci . 1994;  14 3449-3461
    PubMedGoogle Scholar
  • 68 Starr P A, Wichmann T, van Horne C. Intranigral transplantation of fetal substantia nigra allograft in the hemiparkinsonian rhesus monkey.  Cell Transplant . 1999;  8 37-45
    PubMedGoogle Scholar
  • 69 Lindsay R. Neuron saving schemes [news and comments].  Nature . 1995;  373 289-290
    CrossrefPubMedGoogle Scholar
  • 70 Lin L, Doherty D, Lile J, Bextesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons.  Science . 1993;  260 1130-1132
    PubMedGoogle Scholar
  • 71 Beck K, Valverde J, Alexi T. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain.  Nature . 1995;  373 339-341
    CrossrefPubMedGoogle Scholar
  • 72 Kearns C, Gash D. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo.  Brain Res . 1995;  672 104-111
    CrossrefPubMedGoogle Scholar
  • 73 Tomac A, Lindqvist E, Lin L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo.  Nature . 1995;  373 335-339
    CrossrefPubMedGoogle Scholar
  • 74 Gash D, Zhang Z, Ovadia A. Functional recovery in parkinsonian monkeys treated with GDNF.  Nature . 1996;  380 252-255
    CrossrefPubMedGoogle Scholar
  • 75 Kordower J, Palfi S, Chen E Y. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease.  Ann Neurol . 1999;  46(3) 419-424
    CrossrefPubMedGoogle Scholar
  • 76 Kordower J, Emborg M, Bloch J. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.  Science . 2000;  290 767-773
    CrossrefPubMedGoogle Scholar
  • 77 Hughes A J, Daniel S E, Kilford L, Lees A J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases.  J Neurol Neurosurg Psychiatry . 1992;  55 181-184
    CrossrefPubMedGoogle Scholar